Cost-Effectiveness of Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer

Дата публикации: 02-07-2026 00:00:00

This economic evaluation evaluates the cost-effectiveness of perioperative pembrolizumab plus standard of care (SOC) for the treatment of locally advanced head and neck squamous cell carcinoma compared with SOC alone using Canada as a case study.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Pathological response and exploratory assessment of pretreatment PD-L1 combined positive score after four cycles of neoadjuvant pembrolizumab plus chemotherapy in locally advanced head and neck squamous cell carcinoma: a retrospective cohort study	0	13.96	07-08-2026
2	Pembrolizumab Plus Chemotherapy for Cervical Cancer	0	14.76	10-09-2026
3	International Trends in Head and Neck Cancer Mortality	0	7	25-06-2026
4	PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	0	10.08	17-09-2026
5	Lipid nanoparticles deliver one-two punch to shrink resistant oral tumors in preclinical models	0	9.5	23-07-2026
6	Dynamic Quality-of-Life Trajectories After Head and Neck Reconstruction	0	5	25-06-2026
7	Blood Manganese and Risk of Squamous Cell Carcinomas of the Head and Neck	0	7	02-07-2026
8	Cost-Effectiveness of Fecal Immunochemical Testing Alone vs Co-Testing With Helicobacter pylori Stool Antigen	0	9.77	07-07-2026
9	Equity and Cancer Survival Among Veterans Health Administration Patients	0	7	02-07-2026
10	Comparison of Diet and Lifestyle Program With 3 Medication Approaches for Laryngopharyngeal Reflux Disease	0	7	02-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7. Источник: jamanetwork.com.